Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial
Jeffrey S. Weber(Moffitt Cancer Center), Sandra P. D’Angelo(Memorial Sloan Kettering Cancer Center), David R. Minor(Northern California Melanoma Center), F. Stephen Hodi(Dana-Farber Cancer Institute), Ralf Gutzmer(Medizinische Hochschule Hannover), Bart Neyns(Universitair Ziekenhuis Brussel), Christoph Höeller(Medical University of Vienna), Nikhil I. Khushalani(Roswell Park Comprehensive Cancer Center), Wilson H. Miller(McGill University), Christopher D. Lao(University of Michigan–Ann Arbor), Gerald P. Linette(Washington University in St. Louis), L. Thomas(Hôpital Lyon Sud), Paul Lorigan(The Christie Hospital), Kenneth F. Grossmann(Huntsman Cancer Institute), Jessica C. Hassel(German Cancer Research Center), Michele Maio(University of Siena), Mario Sznol(Yale Cancer Center), Paolo A. Ascierto(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Peter Mohr(Elbe Kliniken Stade-Buxtehude), Bartosz Chmielowski(University of California, Los Angeles), Alan H. Bryce(Mayo Clinic in Arizona), Inge Marie Svane(Herlev Hospital), Jean‐Jacques Grob(Aix-Marseille Université), Angela M. Krackhardt(Technical University of Munich), Christine E. Horak(Bristol-Myers Squibb (United States)), Alexandre Lambert(Bristol-Myers Squibb (Belgium)), Arvin Yang(Bristol-Myers Squibb (United States)), James Larkin(Royal Marsden Hospital)
Cited by 2,661
Abstract
Related Papers
No related papers found
Powered by citation graph analysis